Earlier studies suggested that women based better survival than men, probably due to sex-related changes of drug metabolism in estrogen levitra . In the modern chemotherapy era, a detailed analysis of this problem had not been done so far, said Albain, professor, two years.of Hematology / Oncology, Department of Internal Medicine, Loyola University Chicago Stritch School of Medicine, Maywood.
Analyzed for the study , the Southwest Oncology Group Committee on Special Populations and the SWOG Lung Committee data on 1334 patients from six consecutive phase II or III advanced non – small cell lung cancer clinical trial. NSCLC is the most common form of lung cancer.
A surprising and medically important observations from the study was an observed increase in median survival to patients who have Tavocept those who received placebo. The median survival time to patients who have Tavocept has been observed for about 40 days in patients who in patients receiving placebo. Were given for patients with adenocarcinoma, the most common form of lung cancer, to median survival time of about 138 days for patients Tavocept to those on placebo has been increased.
BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. The study received announced results one clinical Phase III trial of Tavocept in patients by advanced non – cell lung. Tavocept is an investigational with a potential of oncology and non-oncology indications the incurred and has been developed by BioNumerik.